Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women .

Phase 4

Terminated

Conditions: Metformin for Obese Pregnant Women

Interventions: Drug: Metformin

First Posted Date: 2022-09-26

Last Posted Date: 2024-02-13

Lead Sponsor: Assiut University

Target Recruit Count: 178

Registration Number: NCT05554679

Locations: 🇪🇬
Assiut university, Asyut, Egypt

Metformin in Patients With Ulcerative Colitis Treated With Mesalamine

Phase 2

Recruiting

Conditions: Inflammatory Bowel Diseases

Interventions: Drug: Metformin

First Posted Date: 2022-09-23

Last Posted Date: 2023-12-28

Lead Sponsor: Tanta University

Target Recruit Count: 60

Registration Number: NCT05553704

Locations: 🇪🇬
Faculty of Medicine, Mansoura University, Mansoura, Egypt

Study to Evaluate the Drug-drug Interactions Between Metformin and AMG 510 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AMG 510
Drug: Metformin

First Posted Date: 2022-09-22

Last Posted Date: 2023-01-11

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT05550129

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

Phase 1

Terminated

Conditions: Leukoplakia
Erythroplakia
Oral Cavity Carcinoma
Proliferative Verrucous Leukoplakia

Interventions: Drug: Metformin
Procedure: Biopsy

First Posted Date: 2022-09-10

Last Posted Date: 2024-04-19

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT05536037

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Metformin
Drug: CIN-107

First Posted Date: 2022-09-02

Last Posted Date: 2023-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 27

Registration Number: NCT05526690

Locations: 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.

Phase 4

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets
Drug: Metformin

First Posted Date: 2022-08-29

Last Posted Date: 2022-08-29

Lead Sponsor: Bing He

Target Recruit Count: 60

Registration Number: NCT05519813

Locations: 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

Early Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Metformin
Behavioral: Lifestyle Modification

First Posted Date: 2022-08-25

Last Posted Date: 2024-08-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 200

Registration Number: NCT05515978

Locations: 🇺🇸
Colorado Research Center, Aurora, Colorado, United States
🇺🇸
UCHealth-Southern Colorado, Colorado Springs, Colorado, United States
🇺🇸
UCHealth-Metro Denver, Denver, Colorado, United States

and more 1 locations